{"id":"W2290950904","doi":"10.1016/s1470-2045(15)00613-0","title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1822,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Calgary","funders":"University of California, Los Angeles; Novartis; Daiichi-Sankyo; Pfizer; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline; U.S. Department of Defense","keywords":"Fulvestrant; Palbociclib; Metastatic breast cancer; Medicine; Placebo; Internal medicine; Oncology; Gynecology; Cancer; Breast cancer; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002516419,0.002579488,0.003969922,0.0005987741,0.0004052526,0.001291883,0.001357067,0.001918248,0.008257579],"category_scores_gemma":[0.002715634,0.0007694033,0.003839853,0.0005486463,0.001387201,0.001594343,0.0005516667,0.00348331,0.00120975],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001071077,"about_ca_system_score_gemma":0.001029497,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00165235,"about_ca_topic_score_gemma":0.003537167,"domain_scores_codex":[0.9990838,0.0005325862,0.00005834198,0.0001425142,0.00005108925,0.0001316262],"domain_scores_gemma":[0.9990283,0.0003794587,0.0002279654,0.00009109511,0.00005873504,0.0002144248],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9918806,0.0006768257,0.00008925319,0.0005579384,0.0008320248,0.00001315231,0.00002136042,0.0001700934,0.0007900264,0.00005625146,0.0002629912,0.004649439],"study_design_scores_gemma":[0.9849277,0.01371717,0.0003925062,0.00002493217,0.0003705115,0.00001063229,0.00001045584,0.0001669237,0.00009949099,0.00009213231,0.0001793921,0.000008164335],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9691883,0.01538618,0.001928907,0.001315055,0.00176379,0.005205363,0.002014484,0.0003884335,0.002809467],"genre_scores_gemma":[0.9828025,0.00474521,0.001950554,0.001082356,0.0005702908,0.003742935,0.001040534,0.00005032662,0.004015274],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008257579,"threshold_uncertainty_score":0.02762431,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1235990477317247,"score_gpt":0.4149209742192354,"score_spread":0.2913219264875107,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}